Product Description.:
SX
tablet , film-coated , pink , round round
circularBiconvex
XIFAXAN 200 mg (rifaximin) is indicated for the treatment of travelers? diarrhea caused by noninvasive strains of Escherichia coli in patients �� years of age. Escherichia coli is the most common cause of travelers? diarrhea in Latin America, the Caribbean, and Africa.1 XIFAXAN 200 mg, a minimally absorbed (<0.4%) enteric antibiotic, targets pathogenic E coli without causing long-term changes to gut flora balance. XIFAXAN 200 mg is proven to treat travelers? diarrhea, stopping symptoms in 79.2% of patients.
Important Safety Information about XIFAXAN 200 mg
XIFAXAN? (rifaximin) 200 mg Tablets are indicated for the treatment of patients (�� years of age) with travelers? diarrhea caused by noninvasive strains of Escherichia coli. XIFAXAN should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than E coli. XIFAXAN should be discontinued if diarrhea symptoms get worse or persist more than 24 to 48 hours and alternative antibiotic therapy should be considered. E coli has been shown to develop resistance to rifaximin in vitro. However, the clinical significance of such an effect has not been studied.
In clinical trials, XIFAXAN was generally well tolerated. The most common side effects (vs placebo) were flatulence 11.3% (vs 19.7%), headache 9.7% (vs 9.2%), abdominal pain 7.2% (vs 10.1%), rectal tenesmus 7.2% (vs 8.8%), defecation urgency 5.9% (vs 9.2%), and nausea 5.3% (vs 8.3%).
